• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

分子动力学模拟揭示了CD137L与CD137三聚化增强的相互作用。

MD Simulation Reveals a Trimerization-Enhanced Interaction of CD137L with CD137.

作者信息

Wang Hefeng, Wu Jianhua, Fang Ying, Li Quhuan

机构信息

School of Biology and Biological Engineering, South China University of Technology, Guangzhou 510006, China.

出版信息

Int J Mol Sci. 2025 Feb 22;26(5):1903. doi: 10.3390/ijms26051903.

DOI:10.3390/ijms26051903
PMID:40076530
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11899465/
Abstract

CD137 is a prominent costimulatory molecule of the tumor necrosis factor (TNF) receptor superfamily that activates T cells through a complex bidirectional signaling process involving CD137L. The clinical value of immunotherapies underscores the potential of CD137L/CD137 as an effective target for boosting antitumor immune responses; however, the intricate mechanisms governing these interactions have not been fully elucidated. Herein, we constructed various oligomeric states of CD137L (monomeric, dimeric, and trimeric CD137L) and explored their interactions with CD137 using molecular dynamics simulations. Our findings revealed that trimeric CD137L exhibits higher thermal stability but reduced binding affinity for CD137 compared with the dimer form, with the A'B' loop of CD137L playing a critical role in both structural stability and promoting CD137 interactions. Notably, the formation of hexameric structures enhanced the binding affinity and stability. This study provides valuable insights into the CD137L/CD137 bidirectional signaling mechanisms, which may inform the design of next-generation CD137 agonists. Ultimately, these advancements may improve cancer immunotherapy strategies, aiming to enhance therapeutic outcomes for patients through more effective and targeted therapies.

摘要

CD137是肿瘤坏死因子(TNF)受体超家族中一种重要的共刺激分子,它通过涉及CD137L的复杂双向信号传导过程激活T细胞。免疫疗法的临床价值凸显了CD137L/CD137作为增强抗肿瘤免疫反应的有效靶点的潜力;然而,这些相互作用的复杂机制尚未完全阐明。在此,我们构建了CD137L的各种寡聚状态(单体、二聚体和三聚体CD137L),并使用分子动力学模拟探索了它们与CD137的相互作用。我们的研究结果表明,与二聚体形式相比,三聚体CD137L表现出更高的热稳定性,但与CD137的结合亲和力降低,CD137L的A'B'环在结构稳定性和促进CD137相互作用中都起着关键作用。值得注意的是,六聚体结构的形成增强了结合亲和力和稳定性。这项研究为CD137L/CD137双向信号传导机制提供了有价值的见解,这可能为下一代CD137激动剂的设计提供参考。最终,这些进展可能会改善癌症免疫治疗策略,旨在通过更有效和有针对性的治疗提高患者的治疗效果。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5953/11899465/28de02dcce05/ijms-26-01903-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5953/11899465/936c666d43ef/ijms-26-01903-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5953/11899465/a59b8479f2ea/ijms-26-01903-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5953/11899465/2e8b42342206/ijms-26-01903-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5953/11899465/49b4f4653858/ijms-26-01903-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5953/11899465/5275ca44a50f/ijms-26-01903-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5953/11899465/c218190e18df/ijms-26-01903-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5953/11899465/ab87cc675328/ijms-26-01903-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5953/11899465/e3ca587737a8/ijms-26-01903-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5953/11899465/28de02dcce05/ijms-26-01903-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5953/11899465/936c666d43ef/ijms-26-01903-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5953/11899465/a59b8479f2ea/ijms-26-01903-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5953/11899465/2e8b42342206/ijms-26-01903-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5953/11899465/49b4f4653858/ijms-26-01903-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5953/11899465/5275ca44a50f/ijms-26-01903-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5953/11899465/c218190e18df/ijms-26-01903-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5953/11899465/ab87cc675328/ijms-26-01903-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5953/11899465/e3ca587737a8/ijms-26-01903-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5953/11899465/28de02dcce05/ijms-26-01903-g009.jpg

相似文献

1
MD Simulation Reveals a Trimerization-Enhanced Interaction of CD137L with CD137.分子动力学模拟揭示了CD137L与CD137三聚化增强的相互作用。
Int J Mol Sci. 2025 Feb 22;26(5):1903. doi: 10.3390/ijms26051903.
2
CD137 / CD137 ligand signalling regulates the immune balance: A potential target for novel immunotherapy of autoimmune diseases.CD137/CD137 配体信号调节免疫平衡:自身免疫性疾病新型免疫治疗的潜在靶点。
J Autoimmun. 2020 Aug;112:102499. doi: 10.1016/j.jaut.2020.102499. Epub 2020 Jun 4.
3
CD137 ligand reverse signaling skews hematopoiesis towards myelopoiesis during aging.衰老过程中,CD137配体反向信号传导使造血向髓系造血倾斜。
Aging (Albany NY). 2013 Sep;5(9):643-52. doi: 10.18632/aging.100588.
4
Crystal structures of the human 4-1BB receptor bound to its ligand 4-1BBL reveal covalent receptor dimerization as a potential signaling amplifier.人源 4-1BB 受体与其配体 4-1BBL 结合的晶体结构揭示了共价受体二聚化作为一种潜在的信号放大机制。
J Biol Chem. 2018 Jun 29;293(26):9958-9969. doi: 10.1074/jbc.RA118.003176. Epub 2018 May 2.
5
CD137-CD137L Signaling Affects Angiogenesis by Mediating Phenotypic Conversion of Macrophages.CD137-CD137L 信号通过调节巨噬细胞表型转化影响血管生成。
J Cardiovasc Pharmacol. 2020 Feb;75(2):148-154. doi: 10.1097/FJC.0000000000000772.
6
CD137-CD137L interaction regulates atherosclerosis via cyclophilin A in apolipoprotein E-deficient mice.在载脂蛋白E缺陷小鼠中,CD137与CD137L的相互作用通过亲环素A调节动脉粥样硬化。
PLoS One. 2014 Feb 10;9(2):e88563. doi: 10.1371/journal.pone.0088563. eCollection 2014.
7
The Murine CD137/CD137 Ligand Signalosome: A Signal Platform Generating Signal Complexity.鼠源 CD137/CD137 配体信号osome:产生信号复杂性的信号平台。
Front Immunol. 2020 Dec 10;11:553715. doi: 10.3389/fimmu.2020.553715. eCollection 2020.
8
The CD137 Ligand Is Important for Type 1 Diabetes Development but Dispensable for the Homeostasis of Disease-Suppressive CD137 FOXP3 Regulatory CD4 T Cells.CD137 配体对 1 型糖尿病的发展很重要,但对疾病抑制性 CD137+FOXP3+调节性 CD4 T 细胞的稳态是可有可无的。
J Immunol. 2020 Jun 1;204(11):2887-2899. doi: 10.4049/jimmunol.1900485. Epub 2020 Apr 15.
9
Regulatory T Cells Inhibit T Cell Activity by Downregulating CD137 Ligand via CD137 Trogocytosis.调节性 T 细胞通过 CD137 胞吞作用下调 CD137 配体抑制 T 细胞活性。
Cells. 2021 Feb 9;10(2):353. doi: 10.3390/cells10020353.
10
Crystal structure of the m4-1BB/4-1BBL complex reveals an unusual dimeric ligand that undergoes structural changes upon 4-1BB receptor binding.m4-1BB/4-1BBL 复合物的晶体结构揭示了一种不寻常的二聚配体,它在与 4-1BB 受体结合时会发生结构变化。
J Biol Chem. 2019 Feb 8;294(6):1831-1845. doi: 10.1074/jbc.RA118.006297. Epub 2018 Dec 13.

本文引用的文献

1
Targeting the TNF and TNFR superfamilies in autoimmune disease and cancer.针对自身免疫性疾病和癌症中的 TNF 和 TNFR 超家族。
Nat Rev Drug Discov. 2024 Dec;23(12):939-961. doi: 10.1038/s41573-024-01053-9. Epub 2024 Oct 24.
2
Prediction of Threonine-Tyrosine Kinase Receptor-Ligand Unbinding Kinetics with Multiscale Milestoning and Metadynamics.利用多尺度里程碑法和元动力学预测苏氨酸-酪氨酸激酶受体配体的非结合动力学。
J Phys Chem Lett. 2024 Oct 24;15(42):10473-10478. doi: 10.1021/acs.jpclett.4c02332. Epub 2024 Oct 11.
3
Human/mouse CD137 agonist, JNU-0921, effectively shrinks tumors through enhancing the cytotoxicity of CD8 T cells in cis and in trans.
人/鼠 CD137 激动剂 JNU-0921 通过增强顺式和反式 CD8 T 细胞的细胞毒性有效缩小肿瘤。
Sci Adv. 2024 Aug 23;10(34):eadp8647. doi: 10.1126/sciadv.adp8647.
4
Final results of urelumab, an anti-CD137 agonist monoclonal antibody, in combination with cetuximab or nivolumab in patients with advanced solid tumors.urelumab(一种抗 CD137 激动型单克隆抗体)联合西妥昔单抗或纳武利尤单抗治疗晚期实体瘤患者的最终结果。
J Immunother Cancer. 2024 Mar 7;12(3):e007364. doi: 10.1136/jitc-2023-007364.
5
QMrebind: incorporating quantum mechanical force field reparameterization at the ligand binding site for improved drug-target kinetics through milestoning simulations.QMrebind:通过里程碑式模拟在配体结合位点纳入量子力学力场重新参数化以改善药物-靶点动力学
Chem Sci. 2023 Oct 24;14(45):13159-13175. doi: 10.1039/d3sc04195f. eCollection 2023 Nov 22.
6
4-1BB Targeting Immunotherapy: Mechanism, Antibodies, and Chimeric Antigen Receptor T.4-1BB 靶向免疫疗法:机制、抗体和嵌合抗原受体 T 细胞。
Cancer Biother Radiopharm. 2023 Sep;38(7):431-444. doi: 10.1089/cbr.2023.0022. Epub 2023 Jul 11.
7
Targeting CD137 (4-1BB) towards improved safety and efficacy for cancer immunotherapy.针对 CD137(4-1BB)提高癌症免疫治疗的安全性和疗效。
Front Immunol. 2023 Jun 2;14:1208788. doi: 10.3389/fimmu.2023.1208788. eCollection 2023.
8
Delivering co-stimulatory tumor necrosis factor receptor agonism for cancer immunotherapy: past, current and future perspectives.提供共刺激肿瘤坏死因子受体激动剂用于癌症免疫治疗:过去、现在和未来的观点。
Front Immunol. 2023 Apr 25;14:1147467. doi: 10.3389/fimmu.2023.1147467. eCollection 2023.
9
Selectivity and Ranking of Tight-Binding JAK-STAT Inhibitors Using Markovian Milestoning with Voronoi Tessellations.使用 Markovian Milestoning 与 Voronoi Tessellations 对紧密结合的 JAK-STAT 抑制剂进行选择性和排序。
J Chem Inf Model. 2023 Apr 24;63(8):2469-2482. doi: 10.1021/acs.jcim.2c01589. Epub 2023 Apr 6.
10
Moderate Constraint Facilitates Association and Force-Dependent Dissociation of HA-CD44 Complex.中度约束促进 HA-CD44 复合物的缔合和力依赖性解离。
Int J Mol Sci. 2023 Jan 23;24(3):2243. doi: 10.3390/ijms24032243.